Illinois Compiled Statutes
ILCS Listing
Public
Acts Search
Guide
Disclaimer
Information maintained by the Legislative
Reference Bureau
Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process.
Recent laws may not yet be included in the ILCS database, but they are found on this site as Public
Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the
Guide.
Because the statute database is maintained primarily for legislative drafting purposes,
statutory changes are sometimes included in the statute database before they take effect.
If the source note at the end of a Section of the statutes includes a Public Act that has
not yet taken effect, the version of the law that is currently in effect may have already
been removed from the database and you should refer to that Public Act to see the changes
made to the current law.
410 ILCS 416/10 (410 ILCS 416/10)
Sec. 10. Definitions. In this Act: "Clinical trial" means (i) a research study that subjects an individual to a new cancer treatment, including a medication, chemotherapy, adult stem cell therapy, or other treatment or (ii) a voluntary research study conducted on people and designed to answer specific questions about the safety or effectiveness of a drug, vaccine, therapy, medical device, medical diagnostic, or new way of using an existing treatment to treat or diagnose a condition. "Clinical trial sponsor" means a person, physician, professor, or researcher who initiates a clinical trial; a government entity or agency that initiates a clinical trial; or an industry, including, but not limited to, a pharmaceutical, biotechnology, or medical device company, that initiates a clinical trial. "Condition" means a disease, disorder, syndrome, illness, or injury, including, but not limited to, cancer, cardiovascular disease, circulatory disease, infectious disease, digestive disease, musculoskeletal disease, nervous system disease, endocrinological disease, metabolic disease, mental health and behavioral disorder, blood disease, and rare diseases. "Independent third-party organization" means an entity or organization, whether public or private, that is not a sponsor or host of a clinical trial, or that is not in any way directly affiliated with a sponsor or host of a clinical trial, and has experience in patient advocacy and direct patient reimbursement of clinical trial participation costs. "Inducement" means providing a person something of value, including money, as part of participation in a clinical trial. "Program" means the clinical trial participation program established under this Act. "Subject" means an individual who participates in the program. "Undue inducement" means the value of something received by a potential clinical trial research subject, which value is so large that it may reasonably cause the research subject to take risks that are not in his or her best interests.
(Source: P.A. 103-227, eff. 6-30-23.) |
|
